Data Center

Rome, Italy

Data Center

Rome, Italy
SEARCH FILTERS
Time filter
Source Type

Zardavas D.,Data Center | Phillips W.A.,The Surgical Center | Loi S.,University of Melbourne
Breast Cancer Research | Year: 2014

PIK3CA mutations represent one of the most common genetic aberrations in breast cancer. They have been reported to be present in over one-third of cases, with enrichment in the luminal and in human epidermal growth factor receptor 2-positive subtypes. Substantial preclinical data on the oncogenic properties of these mutations have been reported. However, whilst the preclinical data have clearly shown an association with robust activation of the pathway and resistance to common therapies used in breast cancer, the clinical data reported up to now do not support that the PIK3CA mutated genotype is associated with high levels of pathway activation or with a poor prognosis. We speculate that this may be due to the minimal use of transgenic mice models thus far. In this review, we discuss both the preclinical and clinical data associated with PIK3CA mutations and their potential implications. Prospective clinical trials stratifying by PIK3CA genotype will be necessary to determine if the mutation also predicts for increased sensitivity to agents targeting the phosphoinositide 3-kinase pathway. © 2014 Zardavas et al.; licensee BioMed Central Ltd.


van der Holt B.,Data Center | Cornelissen J.J.,Erasmus MC Daniel den Hoed
Thrombosis and Haemostasis | Year: 2013

Treatment of acute lymphoblastic leukaemia (ALL) is frequently complicated by venous thromboembolism (VTE). The efficacy and optimal approach of VTE prevention are unclear, particularly in adult patients. We assessed the effect of thromboprophylaxis on symptomatic VTE incidence in cycle 1 of ALL treatment in adult patients. Secondly, we explored potential etiologic factors for VTE and the clinical impact of VTE on ALL outcome. We retrospectively assessed symptomatic VTE incidence and use of thromboprophylaxis in 240 adults treated for newly diagnosed ALL in the Dutch-Belgian HOVON-37 multicentre study (1999-2005). Potential etiologic factors were explored by analysis of patient and disease characteristics, impact of VTE on ALL outcome by analysis of complete remission and overall survival rates. Symptomatic VTE was observed in 24 of 240 patients (10%). Thromboprophylaxis differed by centre (prophylactic fresh frozen plasma (FFP) supplementation or no thromboprophylaxis) and was applied only during L-asparaginase in cycle 1. VTE incidence was significantly lower with FFP supplementation than without FFP (6% vs. 19%; adjusted odds ratio [OR] 0.28; 95% confidence interval [CI] 0.10-0.73). FFP did not influence antithrombin or fibrinogen plasma levels. Patients with VTE in cycle 1 had a significantly poorer complete remission rate (adjusted OR 0.18; 95% CI 0.07-0.50), particularly patients with cerebral venous thrombosis (adjusted OR 0.17; 95% CI 0.04-0.65). Our study suggests that prophylactic FFP supplementation effectively reduces symptomatic VTE incidence during ALL treatment in adults. This should be confirmed in a randomised controlled trial. © Schattauer 2013.


Analysts forecast the Southeast Asia Data Center market to grow at a CAGR of 20.17% during the period 2016-2020. Data Center Market report 2016-2020 focuses on the major drivers and restraints for the key players. Data Center research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market.  The Data Center market research report is a professional and in-depth study on the current state of Data Center Industry. The Data Center Market research report covers the present scenario and the growth prospects of the Southeast Asia Data Center industry for 2016-2020. The services offered by a data center facility can be identified based on a tier system. Every data center is associated with a tier ranking from one to four, which indicates its physical infrastructure, cooling, power, promised uptime, and redundancy levels.  The data center tier system was introduced in 2005 and is developed and maintained by the Telecommunications Industry Association (TIA). The Uptime Institute developed the four tier levels in order to identify whether a data center satisfies business requirements. • Increased demand for cloud data centers • For a full, detailed list, view our report Data Center market report provides key statistics on the market status of the Data Center manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Data Center industry. The Data Center market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market. Data Center market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios. The market is divided into the following segments based on infrastructure:  • IT equipment • Power management solutions • Cooling solutions • General construction • Rack • Security • DCIM Construction of green data centers  • For a full, detailed list, view our report Through the statistical analysis, the report depicts the Southeast Asia Data Center market including capacity, production, production value, cost/profit, supply/demand and import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. ·         What will the market size be in 2020 and what will the growth rate be? ·         What are the key market trends? ·         What is driving this market? ·         What are the challenges to market growth? ·         Who are the key vendors in this market space? ·         What are the market opportunities and threats faced by the key vendors? ·         What are the strengths and weaknesses of the key vendors? • High construction and installation costs • For a full, detailed list, view our report The report then estimates 2016-2020 market development trends of Data Center market. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Data Center market before evaluating its feasibility. For Any Query, Contact Our Expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/10290375 About 360 Market Updates: 360 Market Sales Updates is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.


Zhang P.,Data Center | Ren Y.,Tsinghua University | Zhang B.,CAS Academy of Mathematics and Systems Science
Neurocomputing | Year: 2012

Manifold learning is a hot research topic in the field of computer science. A crucial issue with current manifold learning methods is that they lack a natural quantitative measure to assess the quality of learned embeddings, which greatly limits their applications to real-world problems. In this paper, a new embedding quality assessment method for manifold learning, named as normalization independent embedding quality assessment (NIEQA) is proposed. Compared with current assessment methods which are limited to isometric embeddings, the NIEQA method has a much larger application range due to two features. First, it is based on a new measure which can effectively evaluate how well local neighborhood geometry is preserved under normalization, hence it can be applied to both isometric and normalized embeddings. Second, it can provide both local and global evaluations to output an overall assessment. Therefore, NIEQA can serve as a natural tool in model selection and evaluation tasks for manifold learning. Experimental results on benchmark data sets validate the effectiveness of the proposed method. © 2012 Elsevier B.V.


Corchia C.,International Center on Birth Defects and Prematurity | Orlando S.M.,Data Center
Journal of Maternal-Fetal and Neonatal Medicine | Year: 2012

Objectives: To investigate the relationships between mortality of infants <32 weeks gestation and neonatal intensive care units' (NICUs) volume of activity, daily number of high-dependent infants (HDIs) and geographical area in Italy. Methods: The study involved 105 neonatal units in 2005. Data were collected prospectically and through monthly cross-sectional investigations. Patients receiving respiratory care were defined as HDIs. Univariate and multivariable methods were used for analysis. Results: Babies enrolled were 4014. The overall mortality was 18.8%. An adjusted nearly two-fold increase in mortality was found in Southern compared to Northern regions. Volume of activity was not associated with mortality. When compared to infants admitted to NICUs in the highest tertile of the median number of HDIs/day (>2.5 patients/day), the adjusted odds ratios were 1.52 (95% CI = 1.14-2.02) for those in the 2nd tertile (1.1-2.5 patients/day) and 1.47 (95% CI = 1.02-2.13) for those in the lowest tertile (≤1 patient/day). After stratification by geographical area, this relationship was present in Southern, to a lesser extent in Central, but not in Northern regions. Conclusions: In Italy, striking geographical differences in mortality of very preterm infants are present. NICUs' average daily number of HDIs is a better predictor of mortality than the volume of activity. © 2012 Informa UK, Ltd.


Pucciarelli S.,University of Padua | Del Bianco P.,Servizio Sperimentazioni Cliniche e Biostatistica | Efficace F.,Data Center | Serpentini S.,University of Padua | And 5 more authors.
Annals of Surgery | Year: 2011

Objective: To prospectively describe patient-reported outcomes (PROs) after preoperative chemoradiotherapy (pCRT) for rectal cancer. Background: Little evidence is available on PROs after pCRT for rectal cancer. PATIENTS AND Methods: Patients with rectal cancer, candidates to receive pCRT, were enrolled in a multicenter prospective observational trial. Health-related quality of life was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and its colorectal cancer module (QLQ-CR38), and fecal incontinence and bowel function were evaluated using the fecal incontinence score questionnaire and a set of ad hoc questions. Questionnaires were filled out before CRT (t0), 2 to 3 weeks after completion of CRT (t1), and at 6 (t2) and 12 months (t3) after surgery. Primary analysis of selected scales included: global quality of life, physical functioning, social functioning, fatigue, body image, future prospective, and gender-related sexual problems. Results: Of 149 eligible patients, questionnaires were completed in 100%, 95%, 88% and 77% of cases at t0, t1, t2, and t3, respectively. At t3, 78% of patients reported stool fractionation and 72% sensation of incomplete defecation. Only 14% of patients had optimal continence. Physical/social functioning, fatigue, and body image showed a decrease just after pCRT and returned to baseline levels at 1 year after treatment. Global quality of life was stable over time. Male sexual problems were greatly impaired throughout the study period (P < 0.001) with major clinically meaningful changes between baseline and 1 year after treatment. Background: These findings add to the body of evidence available regarding pCRT and help clinicians to make more informed treatment decisions. © 2010 Lippincott Williams & Wilkins.


Kasper B.,University of Mannheim | Sleijfer S.,Netherlands Cancer Institute | Litiere S.,Data Center | Marreaud S.,Data Center | And 5 more authors.
Annals of Oncology | Year: 2014

Background: Pazopanib recently received approval for the treatment of certain soft tissue sarcoma (STS) subtypes. We conducted a retrospective analysis on pooled data from two EORTC trials on pazopanib in STS in order to characterize long-term responders and survivors. Patients and methods: Selected patients were treated with pazopanib in phase II (n = 118) and phase III study (PALETTE) (n = 226). Combined median progression-free survival (PFS) was 4.4 months; the median overall survival (OS) was 11.7 months. Thirty-six percent of patients had a PFS ≥ 6 months and were defined as long-term responders; 34% of patients survived ≥18 months, defined as long-term survivors. Patient characteristics were studied for their association with long-term outcomes. Results: The median follow-up was 2.3 years. Patient characteristics were compared among four subgroups based on short-/long-term PFS and OS, respectively. Seventy-six patients (22.1%) were both long-term responders and long-term survivors. The analysis confirmed the importance of known prognostic factors in metastatic STS patients treated with systemic treatment, such as performance status and tumor grading, and additionally hemoglobin at baseline as new prognostic factor. We identified 12 patients (3.5%) remaining on pazopanib for more than 2 years: nine aged younger than 50 years, nine females, four with smooth muscle tumors and nine with low or intermediate grade tumors at initial diagnosis. The median time on pazopanib in these patients was 2.4 years with the longest duration of 3.7 years. Conclusions: Thirty-six percent and 34% of all STS patients who received pazopanib in these studies had a long PFS and/or OS, respectively. For more than 2 years, 3.5% of patients remained progression free under pazopanib. Good performance status, low/intermediate grade of the primary tumor and a normal hemoglobin level at baseline were advantageous for long-term outcome. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.


Trimbos B.,Leiden University | Timmers P.,Medisch Centrum Rijnmond Zuid | Timmers P.,Data Center | Pecorelli S.,University of Brescia | And 5 more authors.
Journal of the National Cancer Institute | Year: 2010

A long-term follow-up analysis of the randomized clinical trial Adjuvant Chemotherapy in Ovarian Neoplasm (ACTION) from the European Organization for Research and Treatment of Cancer was undertaken to determine whether the original results with a median follow-up of 5.5 years could be verified after longer follow-up with more events. In the ACTION trial, 448 patients with early ovarian cancer were randomly assigned, after surgery, to adjuvant chemotherapy or to observation (no further treatment). The original analysis found that adjuvant chemotherapy improved recurrence-free survival but not overall survival and found in a subgroup analysis that completeness of surgical staging was an independent prognostic factor, with better recurrence-free and overall survival among those with complete (optimal) surgical staging. After a median follow-up of 10.1 years, we analyzed the more mature data from the ACTION trial and found support for most of the main conclusions of the original analysis, except that overall survival after optimal surgical staging was improved, even among patients who received adjuvant chemotherapy (hazard ratio of death = 1.89, 95% confidence interval = 0.99 to 3.60; overall two-sided log-rank test P =. 05). More cancer-specific deaths were observed among nonoptimally staged patients (40 [27%] of the 147 deaths in the observation arm and 11 [14%] of the 76 deaths in the adjuvant chemotherapy arm) than among optimally staged patients (seven [9%] of the 75 deaths in the observation arm and 11 [14%] of the 76 deaths in the adjuvant chemotherapy arm) (two-sided χ2 test for heterogeneity, P =. 06). Thus, completeness of surgical staging in patients with early ovarian cancer was found to be statistically significantly associated with better outcomes, and the benefit from adjuvant chemotherapy appeared to be restricted to patients with nonoptimal surgical staging. © 2010 The Author. Published by Oxford University Press.


Gorham J.,Service des Soins Intensifs et Urgences Oncologiques and Oncologie Thoracique | Ameye L.,Data Center | Berghmans T.,Service des Soins Intensifs et Urgences Oncologiques and Oncologie Thoracique | Sculier J.P.,Service des Soins Intensifs et Urgences Oncologiques and Oncologie Thoracique | Meert A.P.,Service des Soins Intensifs et Urgences Oncologiques and Oncologie Thoracique
Lung Cancer | Year: 2013

Introduction: Currently, there are limited data on the lung cancer patient at the emergency department. Our objective is to review the medical charts of those patients to determine the frequency and main causes of emergency consultations and the predicting factors for hospital admissions and deaths. Methods: We conducted a retrospective study including all patients with lung cancer consulting at the emergency department of a cancer hospital. Results: From January 1, 2008 to December 31, 2010, 269 patients with lung cancer presented at the emergency, corresponding to 548 consultations (8.3% of all 6575 visits). During the same period, 626 patients for lung cancer were treated in our institution meaning that 43% of them are consulting at least once the emergency department during the course of their disease. The main reasons for consultation were respiratory symptoms (22.3%) and fever (19.9%). Emergency visit leads to hospital admission in 63% of the cases. In multivariate analysis, the main independent predictor factor of hospitalisation is arrival by ambulance (odd ratio 12), which is also the principal predictor of death during hospitalisation (odd ratio 9.5). The presence of signs at physical examination is also an important factor. Conclusion: Our study shows that emergency visit is a frequent event for lung cancer patients and has identified simple factors predicting hospitalisation and deaths. © 2012 Elsevier Ireland Ltd.


Mizusawa J.,Data Center
Japanese Journal of Chest Diseases | Year: 2014

Researchers and biostatisticians should collaborate to plan valid an adequate clinical trials to address unmet medical needs in clinical practice. In this manuscript I discuss points pertaining to the planning of clinical trials, which all researchers should understand. © 2014 The Japanese Journal of Chest Diseases.

Loading Data Center collaborators
Loading Data Center collaborators